Navigation Links
Organovo To Present At Lazard Healthcare Conference
Date:11/7/2012

SAN DIEGO, Nov. 7, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQB: ONVO) ("Organovo"), a developer and manufacturer of functional human tissues using a novel three-dimensional  bioprinting technology, today announced that Keith Murphy, Chairman and Chief Executive Officer, will present at the upcoming Lazard Capital Markets 9th Annual Healthcare Conference in New York.  Mr. Murphy is expected to present on Wednesday, November 14, 2012. 

About Organovo Holdings, Inc.

Organovo designs and creates functional human tissues using a proprietary three dimensional bioprinting technology. The Company focuses on developing a range of human tissues and disease models for medical research and therapeutic applications.  The Company's NovoGen three-dimensional bioprinting technology uses a specialized automated platform that works across all tissue and cell types. Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo's technology can also be applied to create surgical tissues for direct therapy. Organovo leads the way in solving complex medical research problems and building the future of medicine. For more information, please visit http://www.organovo.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current report on Form 8-K/A filed on May 11, 2012. We do not undertake to update these forward-looking statements made by us.


'/>"/>
SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
2. Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st
3. Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
4. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
5. Organovo Announces Relocation and Commencement of Operations at Larger Facility
6. Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... , May 19, 2016 ... una sessione orale durante il 52 ° ... n. 8006)    - Le conclusioni dello ... riguarda i pazienti trattati, di cui il 90% presenta una ... sei mesi o più. Il settantadue per cento dei pazienti ...
(Date:5/18/2016)... ... May 18, 2016 , ... ... Camp at The University of Toledo. This two-day camp will take place annually ... explore the field of pharmaceutical sciences in preparation for a university academic program. ...
(Date:5/18/2016)... ... 2016 , ... STACS DNA Inc., the sample tracking software company, today announced ... kit processing to help them save time and reduce errors. , Sexual Assault kits ... processed and victims informed of results. Due to a previous lack of tools, many ...
(Date:5/18/2016)... (PRWEB) , ... May 18, 2016 , ... The Academy ... is now celebrating its dream of reaching a total of $1 million in awarded ... awarded to 10 high school graduates from across the nation has helped bring the ...
Breaking Biology Technology:
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):